Company Overview and News

 
Megaworld acquires South Luzon-based company

2018-07-10 bworldonline
MEGAWORLD Corp. is ramping up its land bank in Cavite and Laguna with the acquisition of a South Luzon-based real estate firm through one of its subsidiaries.
ALGGY GERI ALGGF ELI AGI

 
GERI to open Twin Lakes hotel by yearend

2018-06-28 bworldonline
GLOBAL-ESTATE Resorts, Inc. (GERI) on Thursday said it is on track to open the P1.5-billion Twin Lakes Hotel near Tagaytay by the end of the year.
GERI ELI

 
Empire East launches P10B worth of residential units

2018-06-15 business.inquirer.net
Property developer Empire East Land Holdings Inc. plans to bring to the property market up to P10 billion worth of new residential inventory this year, riding on sustained demand from increasingly affluent local homebuyers.
ELI

9
Andrew Tan steps down as AGI chief executive

2018-06-04 bworldonline
TYCOON Andrew L. Tan has stepped down as chief executive officer of holding company Alliance Global Group, Inc. (AGI), appointing eldest son Kevin Andrew L. Tan to take his place.
PSKXF RWM ALGGY ALGGF GERI PHSXY PSE ELI AGI

Related Articles

ALIM: Alimera Sciences Analysis and Research Report

2018-10-01 - Asif

Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...

DMPI: DelMar Pharmaceuticals Analysis and Research Report

2018-09-25 - Asif

Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

Silicon Investor Message Boards

This table lists all message boards related to PSE:ELI / Empire East Land Holdings, Inc. on message board site Silicon Investor.

Fidelity Select Funds Fidelity Select Funds Fidelity Select Funds Fidelity Funds Fidelity Funds Fidelity Funds
Reliq Health Technologies Inc Reliq Health Technologies Inc Reliq Health Technologies Inc NKTR Drug delivery Company NKTR Drug delivery Company NKTR Drug delivery Company
GUMM - Eliminate the Common Cold GUMM - Eliminate the Common Cold GUMM - Eliminate the Common Cold MELI MercadoLibre MELI MercadoLibre MELI MercadoLibre
Priceline.com (PCLN)...another hot IPO ? Priceline.com (PCLN)...another hot IPO ? Priceline.com (PCLN)...another hot IPO ? Exelixis, Inc. (EXEL) Exelixis, Inc. (EXEL) Exelixis, Inc. (EXEL)
Reliability Inc (REAL) Reliability Inc (REAL) Reliability Inc (REAL) Historyu0027s effect on Religion Historyu0027s effect on Religion Historyu0027s effect on Religion